Shared on18 Sep 25Fair value Increased 1.98%
XP's valuation outlook has shifted as its future P/E multiple dropped sharply and revenue growth forecasts softened, yet the analyst price target was essentially unchanged at $23.50. What's in the News Board meeting held to consider and approve unaudited interim condensed consolidated financial statements as of June 30, 2025.
Shared on27 Aug 25Fair value Increased 3.65%
Analysts have modestly raised XP's price target to $22.84 as bullish sentiment around improved fundamentals offsets bearish concerns over limited upside and competitive challenges. Analyst Commentary Bearish analysts cite concerns over limited upside to justify a downgrade and reduced price target.
Shared on23 Apr 25Fair value Decreased 0.64%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Increased 1.30%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Increased 4.58%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Decreased 3.07%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Increased 1.84%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 0.78%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on12 Mar 25Fair value Decreased 18%
AnalystConsensusTarget has decreased future PE multiple from 13.0x to 11.7x and decreased shares outstanding growth rate from -0.0% to -0.0%.